Pharmacological evaluation of Orai-1 inhibitor in 3-nitropropionic acid-induced Huntington disease

Veerta Sharma; Saravjeet Singh; Takveer Singh

doi:10.1093/jpp/rgag030

March 16, 2026Journal of Pharmacy and Pharmacology

Pharmacological evaluation of Orai-1 inhibitor in 3-nitropropionic acid-induced Huntington disease

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to evaluate the therapeutic effects of Orai-1 inhibition in a Huntington disease model.
Utilized a 3-nitropropionic acid (3-NPA) model in mice to induce Huntington disease symptoms.
Administered the Orai-1 inhibitor Synta-66 to test its effects on neuroprotection.
Conducted behavioral and biochemical assessments to evaluate treatment outcomes.
Synta-66 treatment resulted in significant neuroprotective effects in the mice model.
Behavioral tests showed improved motor function in treated mice compared to non-treated groups.
Biochemical analyses indicated reduced neuronal death markers with Synta-66 administration.

Implication

Evaluation shows Orai-1 inhibitor offers neuroprotection in a Huntington disease model, suggesting therapeutic potential.

Abstract

The findings suggest the therapeutic potential of targeting Orai-1 channel using the inhibitor Synta-66 could serve as a neuroprotective treatment in a 3-NPA-induced HD model in mice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sharma et al. (2026) studied this question.

synapsesocial.com/papers/69e07c972f7e8953b7cbdd37 https://doi.org/10.1093/jpp/rgag030

View Full Paper

Ask AI

Bookmark

Share

Pharmacological evaluation of Orai-1 inhibitor in 3-nitropropionic acid-induced Huntington disease

Key Points

Implication

Abstract

Discussion

Cite This Study

Pharmacological evaluation of Orai-1 inhibitor in 3-nitropropionic acid-induced Huntington disease

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading